Clinical applications of assays for thyrotropin-receptor antibodies in Graves' disease
| Autor: | Ginsberg, J, von Westarp, C |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 1986 |
| Předmět: |
endocrine system
endocrine system diseases Placenta Thyroid Gland Thyrotropin Enzyme-Linked Immunosorbent Assay Receptors Cell Surface Cell Line Iodine Radioisotopes Mice Radioligand Assay Antithyroid Agents Pregnancy Cyclic AMP Animals Humans Autoantibodies Infant Newborn Receptors Thyrotropin Graves Disease Pregnancy Complications Long-Acting Thyroid Stimulator Biological Assay Female hormones hormone substitutes and hormone antagonists Research Article |
| Popis: | Graves' disease is characterized by hyperthyroidism, diffuse goitre, infiltrative ophthalmopathy and, rarely, pretibial myxedema. In 1956 a substance capable of prolonged thyroid stimulation was discovered in the serum of some patients with Graves' disease and termed long-acting thyroid stimulator (LATS). It was shown to be an antibody that could interact with the receptor for thyroid-stimulating hormone (TSH). The term LATS is usually reserved for the activity measured in a laborious in-vivo bioassay in mice. Today the activity of TSH-receptor antibodies (TSH-R Ab) can be measured by in-vitro bioassays or by radioreceptor assays. These assays are now becoming commercially available. TSH-R Ab assays may be useful in predicting the response to therapy for Graves' disease, investigating euthyroid ophthalmopathy and predicting the likelihood of neonatal hyperthyroidism. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|